REYKJAVIK, ICELAND and LONDON, UK (November 06, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and...
LAWRENCEVILLE, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with...
NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan SHELTON, CONNECTICUT /...
AllOne Health Unveils Landmark Work/Life Study: Profile of 59,137 Real-World Cases Shows Wide Range of Everyday Needs Drive EAP Use—Legal,...
Calgary, Alberta--(Newsfile Corp. - November 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading...
RALEIGH, N.C. and TEL-AVIV, Israel, Nov. 4, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty...
Investor event in New York City to provide update on pivotal Phase 3 study of IMNN-001; offering in-person or virtual...
ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis up...
SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has...
OCALA, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that...
Calgary, Alberta--(Newsfile Corp. - October 30, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's...
New multi-modal GenAI solution accelerates report authoring and introduces breakthrough "Figures-to-Text" interpretation for faster, context-aware clinical insights CAMPBELL, Calif., Oct....
Calgary, Alberta--(Newsfile Corp. - October 28, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's...
To enhance and accelerate regulatory dialogue with the FDA To provide strategic guidance across clinical development programsTo bring deep expertise...
Study met primary and secondary endpointsParidiprubart demonstrated a relative reduction in the risk of death of 25%Treatment provided patients with...
NEW HAVEN, Conn., Oct. 28, 2025 (GLOBE NEWSWIRE) -- WHAT: Invivyd, Inc. (Nasdaq: IVVD) is hosting the previously announced live...
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical...
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical...
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical...